Oslo, Norway, 21 January 2020 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, invites to an investor and analyst call Wednesday 22 January 2020 at 08:30 CET regarding the first set of clinical results from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma.
Time: 08:30 CET
Company representatives: Øystein Soug, CEO, Dr. Magnus Jäderberg, Chief Medical Officer and Torbjørn Furuseth, CFO
Language: Norwegian
Format: Introduction + open question & answer session
Questions can also be submitted in advance to renate.birkeli@targovax.com
Please join the event 5-10 minutes prior to the start by using the number and confirmation code below:
Confirmation Code: 5795788
Norway: +47 2350 0296
Sweden: +46 (0)8 5065 3942
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.